SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Citigroup Downgrades Unity Biotechnology to Neutral, Lowers Price Target to $5

Citigroup analyst Yigal Nochomovitz downgrades Unity Biotechnology (NASDAQ:UBX) from Buy to Neutral and lowers the price target from $31 to $5.

Benzinga · 08/18/2020 10:57
Citigroup analyst Yigal Nochomovitz downgrades Unity Biotechnology (NASDAQ: UBX) from Buy to Neutral and lowers the price target from $31 to $5.